BR112021012132A2 - Derivados de quinolina para uso no tratamento ou prevenção de câncer - Google Patents
Derivados de quinolina para uso no tratamento ou prevenção de câncer Download PDFInfo
- Publication number
- BR112021012132A2 BR112021012132A2 BR112021012132-3A BR112021012132A BR112021012132A2 BR 112021012132 A2 BR112021012132 A2 BR 112021012132A2 BR 112021012132 A BR112021012132 A BR 112021012132A BR 112021012132 A2 BR112021012132 A2 BR 112021012132A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- group
- carcinoma
- compound
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306783.4A EP3669874A1 (en) | 2018-12-20 | 2018-12-20 | Quinoline derivatives for use in the treatment or prevention of cancer |
| EP18306783.4 | 2018-12-20 | ||
| PCT/EP2019/086470 WO2020127839A1 (en) | 2018-12-20 | 2019-12-19 | Quinoline derivatives for use in the treatment or prevention of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021012132A2 true BR112021012132A2 (pt) | 2021-09-08 |
Family
ID=65200518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021012132-3A BR112021012132A2 (pt) | 2018-12-20 | 2019-12-19 | Derivados de quinolina para uso no tratamento ou prevenção de câncer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220071985A1 (https=) |
| EP (2) | EP3669874A1 (https=) |
| JP (1) | JP7570641B2 (https=) |
| KR (2) | KR20210136969A (https=) |
| CN (2) | CN113543784A (https=) |
| AU (1) | AU2019408244B2 (https=) |
| BR (1) | BR112021012132A2 (https=) |
| IL (1) | IL284124B2 (https=) |
| MA (1) | MA54512A (https=) |
| MX (1) | MX2021007178A (https=) |
| WO (1) | WO2020127839A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
| CN120152971A (zh) * | 2022-11-25 | 2025-06-13 | 江苏恒瑞医药股份有限公司 | 一种喹啉胺类化合物晶型及其制备方法 |
| WO2025027388A1 (en) | 2023-08-01 | 2025-02-06 | Abivax | Obefazimod for treatment of ulcerative colitis |
| CN121532389A (zh) * | 2023-08-30 | 2026-02-13 | 江苏正大丰海制药有限公司 | 用于调节微小rna-124活性的化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2440547T1 (sl) | 2009-06-12 | 2023-05-31 | Abivax | Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju |
| EP2465502A1 (en) * | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| EP2757161A1 (en) * | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| CN103787992B (zh) * | 2014-01-21 | 2016-04-20 | 华东理工大学 | N,n-双取代苯并氮杂环-2-胺类化合物及其用途 |
| EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
| EP2974729A1 (en) * | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP3059236A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
| JP6474334B2 (ja) | 2015-07-30 | 2019-02-27 | 株式会社キーエンス | 画像検査装置、画像検査方法および画像検査プログラム |
| PT3429998T (pt) * | 2016-03-18 | 2021-11-04 | Prosynergia S A R L | Processo para preparação de derivados de quinolin-2-il-fenilamina e seus sais |
-
2018
- 2018-12-20 EP EP18306783.4A patent/EP3669874A1/en not_active Withdrawn
-
2019
- 2019-12-19 CN CN201980088810.8A patent/CN113543784A/zh active Pending
- 2019-12-19 WO PCT/EP2019/086470 patent/WO2020127839A1/en not_active Ceased
- 2019-12-19 MA MA054512A patent/MA54512A/fr unknown
- 2019-12-19 US US17/416,679 patent/US20220071985A1/en active Pending
- 2019-12-19 KR KR1020217022546A patent/KR20210136969A/ko not_active Ceased
- 2019-12-19 CN CN202411117196.2A patent/CN118986981A/zh active Pending
- 2019-12-19 AU AU2019408244A patent/AU2019408244B2/en active Active
- 2019-12-19 KR KR1020257024660A patent/KR20250117703A/ko active Pending
- 2019-12-19 EP EP19829187.4A patent/EP3897639A1/en active Pending
- 2019-12-19 IL IL284124A patent/IL284124B2/en unknown
- 2019-12-19 JP JP2021535249A patent/JP7570641B2/ja active Active
- 2019-12-19 BR BR112021012132-3A patent/BR112021012132A2/pt unknown
- 2019-12-19 MX MX2021007178A patent/MX2021007178A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220071985A1 (en) | 2022-03-10 |
| EP3669874A1 (en) | 2020-06-24 |
| JP2022513517A (ja) | 2022-02-08 |
| IL284124A (en) | 2021-08-31 |
| IL284124B1 (en) | 2025-03-01 |
| CN118986981A (zh) | 2024-11-22 |
| KR20210136969A (ko) | 2021-11-17 |
| CN113543784A (zh) | 2021-10-22 |
| MA54512A (fr) | 2021-10-27 |
| JP7570641B2 (ja) | 2024-10-22 |
| WO2020127839A1 (en) | 2020-06-25 |
| AU2019408244A1 (en) | 2021-07-08 |
| CA3122912A1 (en) | 2020-06-25 |
| KR20250117703A (ko) | 2025-08-05 |
| AU2019408244B2 (en) | 2025-03-20 |
| IL284124B2 (en) | 2025-07-01 |
| MX2021007178A (es) | 2021-07-07 |
| EP3897639A1 (en) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10724102B2 (en) | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | |
| BR112021012132A2 (pt) | Derivados de quinolina para uso no tratamento ou prevenção de câncer | |
| US8937095B2 (en) | Anticancer compounds | |
| TWI873485B (zh) | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 | |
| BR112019021032A2 (pt) | terapia combinada anticâncer | |
| US20230321042A1 (en) | Combination therapy | |
| JP2020507566A (ja) | ベンゾチオフェンエストロゲン受容体モジュレーター | |
| WO2023056431A1 (en) | Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds | |
| RU2811417C2 (ru) | Производные хинолина для применения в лечении или предупреждении рака | |
| CA3122912C (en) | Quinoline derivatives for use in the treatment or prevention of cancer | |
| BR122024023622A2 (pt) | Uso de um composto derivado de quinolina para tratamento ou prevenção de câncer | |
| HK40118235A (zh) | 用於治疗或预防癌症的喹啉衍生物 | |
| US20250339412A1 (en) | Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine | |
| HK40053004A (en) | Quinoline derivatives for use in the treatment or prevention of cancer | |
| CN117098537A (zh) | 用于癌症治疗的联合疗法 | |
| JP2024537550A (ja) | Ｍａｐｋおよび／またはｐｉ３ｋ経路の調節異常を伴うがんを有する患者に対する治療方法 | |
| BR112019027967A2 (pt) | forma b cristalina isolada, composição farmacêutica, método para o tratamento de um distúrbio, método de um composto ou composição, e, processo para produzir forma b cristalina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024023622-2 PROTOCOLO 870240096989 EM 12/11/2024 17:14. |